Drug
EB 1020
EB 1020: highest development phase Phase 3, developed by Otsuka. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| EB-1020 (Centanafadine) 164.4 mg NCT06926829 | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) |
| EB-1020 (Centanafadine) 164.4 mg NCT06931080 | Phase 2/3 | Attention Deficit Hyperactivity Disorder (ADHD) |
Latest
No recent events.
Follow EB 1020 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.